What is ATRC's market cap?

$3.33B, based on the Nov 4 close of $65.53.

What is ATRC's P/E ratio?

315.9× trailing-twelve-month earnings of $10.55M.

Does AtriCure pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ATRC is sold short?

4.9M shares, 10.0% of float, as of Oct 15, 2026.

What sector is ATRC in?

Healthcare, in the Surgical Instruments industry.

NASDAQ · ATRCHealthcareSurgical Instruments

AtriCure, Inc. (ATRC)

$65.53+8.48%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$65.53▲ 100.09% in range

Nov 4, 2025Low $25.86 · High $65.53Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

AtriCure closed at $65.53 on Nov 4, up 8.48% — matching its 52-week closing high. Volume of 1.3M shares was 1.80× its 20-day average (above normal).

Split-adjusted performance: +22.1% over one month, +134.0% over six months, +92.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $153.60M, up 12.8% from a year earlier, with a net margin of 5.8%.

Short interest was 4.9M shares at the Oct 15 settlement, up 1.4% from the prior report (10.0% of float, 5.2 days to cover).

Market cap$3.33B50.9M shares

Revenue · quarter$153.6M+12.8% YoY

Diluted EPS$0.18—

P/E · TTM315.9×P/S 5.9×

Net margin5.8%Gross 77.2%

Dividend yieldNone

52-week range25.86 – 65.530.0% from high

Volume1.3M1.80× 20-day avg

Volatility · 60d40.1%Annualised

Short % of float10.0%5.2 days to cover

Net cash$106.8MCash $167.8M

Next earnings—Not scheduled

Split-adjusted performance

1W +6.7%1M +22.1%3M +65.9%6M +134.0%YTD +65.6%1Y +92.6%3Y +95.5%5Y −13.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum97

Revenue growth59

Net margin70

Value (low P/E)3

Size80

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →

Shares short4.9M+1.4% vs prior

Days to cover5.2Settled Oct 15

% of float10.0%

Short vol. 10d63.0%of daily volume

Closest peers by size in Surgical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ATRCAtriCure	$65.53	+8.48%	+134.0%	+12.8%	5.8%	315.9	$3.33B
PLSEPulse Biosciences, Inc Common Stock (DE)	$57.06	+9.31%	+197.0%	—	−5681.3%	—	$4.07B	Compare
ICUIICU Medical	$172.62	+6.67%	+44.3%	+0.5%	3.5%	143.5	$4.32B	Compare
UFPTUFP Technologies	$329.82	+17.66%	+51.2%	+15.1%	12.0%	35.3	$2.55B	Compare
IRTCiRhythm Holdings	$134.00	+6.04%	+13.8%	+20.1%	−0.2%	—	$4.42B	Compare
HTFLHeartflow	$56.57	+3.99%	+86.8%	—	−24.6%	—	$4.92B	Compare
MMEDMiniMed Group	$19.29	+2.33%	—	—	0.0%	—	$5.43B	Compare
MMSIMerit Medical Systems	$90.63	+7.69%	+47.1%	+8.4%	10.2%	33.9	$5.43B	Compare
LMATLeMaitre Vascular	$87.92	+9.08%	−20.2%	+9.6%	24.2%	30.6	$2.01B	Compare

News about AtriCure

All news →

Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and MedtronicGlobeNewswire Inc. · Aug 26, 2026▲ Positive Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for InvestorsThe Motley Fool · Aug 7, 2026▲ Positive

Quick answers

What does AtriCure do?: AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others.
What is ATRC's market cap?: $3.33B, based on the Nov 4 close of $65.53.
What is ATRC's P/E ratio?: 315.9× trailing-twelve-month earnings of $10.55M.
Does AtriCure pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ATRC is sold short?: 4.9M shares, 10.0% of float, as of Oct 15, 2026.
What sector is ATRC in?: Healthcare, in the Surgical Instruments industry.

About AtriCure

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.

HQ: Mason, OH1,350 employeesListed Aug 5, 2005atricure.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology